MOBILE, Ala. / Apr 25, 2023 / Business Wire / CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced that it will release its financial results for the first quarter ended March 31, 2023, on Tuesday, May 9, 2023, before the market opens. The Company will host a conference call at 8:30 a.m. Eastern Time that same day.
The live broadcast of CPSI’s conference call will be available online at the Company’s website, www.cpsi.com. The 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
About CPSI
CPSI is a leading provider of healthcare solutions and services for community hospitals, their clinics and post-acute care facilities. Founded in 1979, CPSI is the parent of six companies – Evident, LLC, American HealthTech, Inc., TruBridge, LLC, iNetXperts, Corp. d/b/a Get Real Health, TruCode LLC, and Healthcare Resource Group, Inc. Our combined companies are focused on helping improve the health of the communities we serve, connecting communities for a better patient care experience, and improving the financial operations of our customers. Evident provides comprehensive EHR solutions for community hospitals and their affiliated clinics. American HealthTech is one of the nation’s largest providers of EHR solutions and services for post-acute care facilities. TruBridge focuses on providing business, consulting, and managed IT services, along with its complete RCM solution, for all care settings. Get Real Health focuses on solutions aimed at improving patient engagement for individuals and healthcare providers. TruCode provides medical coding software that enables complete and accurate code assignment for optimal reimbursement. HRG provides specialized RCM solutions for facilities of all sizes. For more information, visit www.cpsi.com.
Last Trade: | US$23.52 |
Daily Change: | -0.27 -1.13 |
Daily Volume: | 122,094 |
Market Cap: | US$351.150M |
May 07, 2025 March 10, 2025 February 12, 2025 February 11, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load